Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review.

Annals of palliative medicine - 1 Jun 2021

Long Yaling, Tang Yuan, Cai Chengzhi, Yu Min, Zhang Min, Chen Rongrong, Huang Meijuan

Abstract excerpt

Immune checkpoint inhibitors (ICI) monotherapy or combination therapies have become increasingly popular in patients with advanced non-small cell lung cancer (NSCLC). However, there are still many unknowns concerning the predictive bio-markers and resistance mechanisms to immunotherapy. Patients with primary tumor STK11 mutation reportedly to have a lower response rate than the STK11 wild-type and possibly a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms, Hereditary Nonpolyposis

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Protein Serine-Threonine Kinases

Source

Identifiers

PMID: 33832284
DOI: 10.21037/apm-20-1639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review.PMID 33832284Read ↗

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration.Semantic proximity Read ↗

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.Semantic proximity Read ↗

<i>STK11</i> and <i>KEAP1</i> Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma CohortSemantic proximity Read ↗

Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.Semantic proximity Read ↗

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.Semantic proximity Read ↗

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.Semantic proximity Read ↗

Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.Semantic proximity Read ↗

Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.Semantic proximity Read ↗

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.Semantic proximity Read ↗

Long-term benefit of immunotherapy in a patient with mismatch repair deficient/microsatellite instability-high/high tumor mutational burden lung cancer: case report and literature reviewSemantic proximity Read ↗

STK11 genetic alterations in metastatic EGFR mutant lung cancerSemantic proximity Read ↗

Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.